Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimebon in moderate-to-severe Alzheimer's disease
NCT00912288Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Sep 2009
- Primary completion
- Aug 2010
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Dimebon with Placebo (2 arms). Primary endpoints: Severe Impairment Battery at Week 26 and Alzheimer's Disease Cooperative Study - Activities of Daily Living (Severe) at Week 26. Started Sep 2009; status: terminated.
02
Drugs
latrepirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00912288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00912288.